[18F]FDG positron emission tomography within two weeks of starting erlotinib therapy can predict response in non-small cell lung cancer patients

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Hachemi, Mammar ^a,b   Couturier, Olivier ^a,b,c   Vervueren, Laurent ^a,b   Fosse, Pacôme ^a,b   Lacoeuille, Franck ^a,b,c   Urban, Thierry ^a,b,c   Hureaux, José ^a,b,c  

^a LUNAM Universite   (France)

^b UNIVERSITÉ D'ANGERS   (France)

^c UNIVERSITÉ D'ANGERS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ERLOTINIB; FLUORODEOXYGLUCOSE F 18; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; DISEASE CLASSIFICATION; FALSE PROGRESSIVE DISEASE; FEMALE; HUMAN; IMAGE ANALYSIS; LUNG NON SMALL CELL CANCER; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RESPONSE EVALUATION CRITERIA IN SOLID TUMOR 1.1 CRITERIA; TREATMENT DURATION; TREATMENT RESPONSE; TRUE NONPROGRESSIVE DISEASE; TRUE PROGRESSIVE DISEASE; TUMOR RESPONSE; AGED; CLINICAL TRIAL; DISEASE FREE SURVIVAL; LUNG TUMOR; MIDDLE AGED; MORTALITY; RADIOGRAPHY; SURVIVAL RATE; TIME;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RADIOPHARMACEUTICALS; SURVIVAL RATE; TIME FACTORS;

EID: 84895534298     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087629     Document Type: Article

References (37)

1. Ferlay J, Parkin DM, Steliarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46: 765-781.
2. Jemal A, Bray F, CenterMM, FerlayJ, WardE, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
3. (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Nonsmall Cell Lung Cancer Collaborative Group. BMJ 311: 899-909.
4. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, et al. (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92-98. (Pubitemid 34438899)
5. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139. (Pubitemid 38637993)
6. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, et al. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957.
7. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, et al. (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13: 239-246.
8. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123-132. (Pubitemid 41058344)
9. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczesna A, et al. (2010) Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11: 521-529.
10. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207-214. (Pubitemid 11167383)
11. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216.
12. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, et al. (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247.
13. Fischer BM, Mortensen J, Hojgaard L (2001) Positron emission tomography in the diagnosis and staging of lung cancer: a systematic, quantitative review. Lancet Oncol 2: 659-666. (Pubitemid 33085811)
14. Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, et al. (2003) Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 348: 2500-2507. (Pubitemid 36706537)
15. Vansteenkiste JF, Stroobants SG, Dupont PJ, De Leyn PR, Verbeken EK, et al. (1999) Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol 17: 3201-3206. (Pubitemid 29470652)
16. Berghmans T, Dusart M, Paesmans M, Hossein-Foucher C, Buvat I, et al. (2008) Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol 3: 6-12.
17. Dinan MA, Curtis LH, Carpenter WR, Biddle AK, Abernethy AP, et al. (2012) Stage migration, selection bias, and survival associated with the adoption of positron emission tomography among medicare beneficiaries with non-small-cell lung cancer, 1998-2003. J Clin Oncol 30: 2725-2730.
18. Velazquez ER, Aerts HJ, Oberije C, De Ruysscher D, Lambin P (2010) Prediction of residual metabolic activity after treatment in NSCLC patients. Acta Oncol 49: 1033-1039.
19. Aukema TS, Kappers I, Olmos RA, Codrington HE, van Tinteren H, et al. (2010) Is 18F-FDG PET/CT useful for the early prediction of histopathologic response to neoadjuvant erlotinib in patients with non-small cell lung cancer? J Nucl Med 51: 1344-1348.
20. planned T, Scheffler M, Nogova L, Kobe C, Engel-Riedel W, et al. (2011) Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography. J Clin Oncol 29: 1701-1708.
21. Su H, Bodenstein C, Dumont RA, Seimbille Y, Dubinett S, et al. (2006) Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res 12: 5659-5667. (Pubitemid 44629592)
22. Ullrich RT, Zander T, Neumaier B, Koker M, Shimamura T, et al. (2008) Early detection of erlotinib treatment response in NSCLC by 3′-deoxy- 3′-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET). PLoS One 3: e3908.
23. Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 50 Suppl 1: 122S-150S.
24. Stroobants S, Goeminne J, Seegers M, Dimitrijevic S, Dupont P, et al. (2003) 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 39: 2012-2020. (Pubitemid 37297757)
25. Van den Abbeele AD (2008) The lessons of GIST-PET and PET/CT: a new paradigm for imaging. Oncologist 13 Suppl 2: 8-13.
26. Mileshkin L, Hicks RJ, Hughes BG, Mitchell PL, Charu V, et al. (2011) Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib. Clin Cancer Res 17: 3304-3315.
27. Benz MR, Herrmann K, Walter F, Garon EB, Reckamp KL, et al. (2011) (18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib. J Nucl Med 52: 1684-1689.
28. Kahraman D, Scheffler M, Zander T, Nogova L, Lammertsma AA, et al. (2011) Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3′-deoxy-3′-18F- fluorothymidine PET. J Nucl Med 52: 1871-1877.
29. Bjurberg M, Henriksson E, Brun E, Ekblad L, Ohlsson T, et al. (2009) Early changes in 2-deoxy-2-[18F]fluoro-D-glucose metabolism in squamous-cell carcinoma during chemotherapy in vivo and in vitro. Cancer Biother Radiopharm 24: 327-332.
30. Messiou C, Cook G, Reid AH, Attard G, Dearnaley D, et al. (2011) The CT flare response of metastatic bone disease in prostate cancer. Acta Radiol 52: 557-561.
31. Krupitskaya Y, Eslamy HK, Nguyen DD, Kumar A, Wakelee HA (2009) Osteoblastic bone flare on F18-FDG PET in non-small cell lung cancer (NSCLC) patients receiving bevacizumab in addition to standard chemotherapy. J Thorac Oncol 4: 429-431.
32. Biersack HJ, Bender H, Palmedo H (2004) FDG-PET in monitoring therapy of breast cancer. Eur J Nucl Med Mol Imaging 31 Suppl 1: S112-117. (Pubitemid 38833040)
33. Mortimer JE, Dehdashti F, Siegel BA, Trinkaus K, Katzenellenbogen JA, et al. (2001) Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 19: 2797-2803. (Pubitemid 32538187)
34. Lind JS, Postmus PE, Smit EF (2010) Osteoblastic bone lesions developing during treatment with erlotinib indicate major response in patients with non-small cell lung cancer: a brief report. J Thorac Oncol 5: 554-557.
35. Kobe C, Scheffler M, Holstein A, Zander T, Nogova L, et al. (2012) Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib. Eur J Nucl Med Mol Imaging 39: 1117-1127.
36. Ciuleanu T, Stelmakh L, Cicenas S, Miliauskas S, Grigorescu AC, et al. (2012) Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol 13: 300-308.
37. Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, et al. (2013) Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol 14: 981-988.